Form 4: Arcutis Executive Sells Shares for Tax Obligations

Arcutis Biotherapeutics' SVP General Counsel, Masaru Matsuda, sold shares to cover tax withholding obligations related to Restricted Stock Unit vesting.

Summary

• Masaru Matsuda, SVP General Counsel and Corporate Secretary of Arcutis Biotherapeutics, Inc. (ARQT), reported sales of common stock.
• The transactions occurred on November 19, 2025, and were made pursuant to a Rule 10b5-1 plan.
• A total of 989 shares were sold at a weighted average price of $27.9541 per share, with prices ranging from $27.21 to $28.21.
• An additional 1,561 shares were sold at a weighted average price of $28.5 per share, with prices ranging from $28.24 to $28.95.
• These sales were executed to cover tax withholding obligations in connection with the vesting of Restricted Stock Units.
• Following these transactions, Matsuda beneficially owns 151,476 shares of Arcutis Biotherapeutics common stock.

Sentiment

Score: 5

Explanation: This is a neutral event, representing a routine transaction for tax purposes related to RSU vesting, not indicative of positive or negative sentiment towards the company's prospects or a change in management confidence.

Stakeholder Impact

• The sale of shares by an executive for tax purposes is a routine event and is unlikely to have a significant direct impact on shareholders, employees, customers, suppliers, or creditors.

Key Dates

Recommendation

The reported transaction is a routine sale of shares by an executive to cover tax obligations associated with the vesting of Restricted Stock Units. Such transactions are common and generally do not reflect a change in management's confidence in the company's future or warrant a change in investment recommendation based solely on this filing.

Keywords

Arcutis Biotherapeutics, ARQT, Masaru Matsuda, Insider Trading, Form 4, Stock Sale, Restricted Stock Units, Tax Withholding